Quantum Biopharma (QNTM) News Today $18.86 +3.49 (+22.71%) As of 03:40 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock QNTM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Quantum Biopharma (NASDAQ:QNTM) Stock Rating Upgraded by Wall Street ZenJune 8, 2025 | americanbankingnews.comQuantum BioPharma clarifies misinformation on stock name, RTO rumorsJune 4, 2025 | investing.comQuantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd WellnessJune 4, 2025 | nasdaq.comQuantum BioPharma Clarifies It Has Not Changed Its NameJune 3, 2025 | globenewswire.comiNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJune 2, 2025 | globenewswire.comQuantum BioPharma settles disputes with former CEOJune 1, 2025 | uk.investing.comWhat's Going On With Quantum Biopharma Stock Today?May 30, 2025 | benzinga.comQuantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariMay 30, 2025 | globenewswire.comQuantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.May 29, 2025 | globenewswire.comQuantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28, 2025 | globenewswire.comQuantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic GrowthMay 21, 2025 | nasdaq.comQuantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple SclerosisMay 20, 2025 | globenewswire.comQuantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000May 19, 2025 | globenewswire.comQuantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare ConferenceMay 16, 2025 | globenewswire.comQuantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND SubmissionMay 13, 2025 | nasdaq.comQuantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple SclerosisMay 12, 2025 | globenewswire.comQuantum BioPharma Ltd. (QNTM) Business Update Conference Call TranscriptMay 6, 2025 | seekingalpha.comQuantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/SpoofingMay 5, 2025 | globenewswire.comQuantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern TimeApril 24, 2025 | globenewswire.comQuantum BioPharma adds Kevin Malone as advisorApril 24, 2025 | uk.investing.comQuantum Group appoints Malone as advisor to Board of DirectorsApril 23, 2025 | markets.businessinsider.comQuantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board AdvisorApril 22, 2025 | globenewswire.comQuantum Group wins reconsideration motion by Dr. Bokhari at CoA for OntarioApril 14, 2025 | markets.businessinsider.comQuantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for OntarioApril 14, 2025 | globenewswire.comQuantum BioPharma’s licensee expands retail reach with AATAC dealApril 12, 2025 | uk.investing.comQuantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto RicoApril 3, 2025 | globenewswire.comQuantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple SclerosisApril 1, 2025 | globenewswire.comQuantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved TermsMarch 31, 2025 | globenewswire.comQuantum BioPharma reports progress in drug trialsMarch 30, 2025 | uk.investing.comQuantum BioPharma reports FY24 net loss $14.9M vs. $18.2M last yearMarch 28, 2025 | markets.businessinsider.comQuantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going ConcernMarch 28, 2025 | globenewswire.comQuantum Group announces licensee expands unbuzzd lineupMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail SalesMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Stock Soars After Licensee Celly Nutrition Releases New Format Of Alcohol Detox Product – Retail Shrugs It OffMarch 26, 2025 | msn.comQuantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other CryptocurrenciesMarch 20, 2025 | globenewswire.comQuantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302February 26, 2025 | markets.businessinsider.comQuantum BioPharma engages MZ Group for strategic IR, communications pogramFebruary 11, 2025 | markets.businessinsider.comQuantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications ProgramFebruary 11, 2025 | globenewswire.comQuantum BioPharma engages Enterprise Canada, Empire for PR, investor programsFebruary 10, 2025 | markets.businessinsider.comQuantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness ProgramsFebruary 10, 2025 | globenewswire.comCelly Nutrition targets IPO with $10 million capital raiseFebruary 6, 2025 | msn.comQNTM Stock trading resumesFebruary 6, 2025 | markets.businessinsider.comQNTM Stock trading halted, volatility trading pauseFebruary 6, 2025 | markets.businessinsider.comQuantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical StudyFebruary 6, 2025 | globenewswire.comQuantum Group announces results from unbuzzd trialFebruary 4, 2025 | markets.businessinsider.comQuantum Biopharma Announces the Success of unbuzzd™ Clinical TrialFebruary 4, 2025 | globenewswire.comQuantum BioPharma approved to dual list on UpstreamJanuary 8, 2025 | markets.businessinsider.comQuantum Biopharma Ltd.: Quantum Biopharma Announces Closing of Second TrancheDecember 20, 2024 | finanznachrichten.deQuantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in CryptocurrencyDecember 20, 2024 | globenewswire.comHow This $4 Stock is Taking on Wall Street's Big Banks with a $700 Million LawsuitDecember 18, 2024 | msn.com Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address QNTM Media Mentions By Week QNTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNTM News Sentiment▼1.010.87▲Average Medical News Sentiment QNTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNTM Articles This Week▼21▲QNTM Articles Average Week Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Puma Biotechnology News SELLAS Life Sciences Group News Janone News LifeVantage News Prime Medicine News Alpha Cognition News Aclaris Therapeutics News Alumis News Spero Therapeutics News Molecular Partners News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNTM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
